Cancer immune evasion through loss of MHC class I antigen presentation
K Dhatchinamoorthy, JD Colbert, KL Rock - Frontiers in immunology, 2021 - frontiersin.org
Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …
expressed genes and then transport and display this antigenic information on the cell …
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Epigenetic mechanisms play vital roles not only in cancer initiation and progression, but also
in the activation, differentiation and effector function (s) of immune cells. In this review, we …
in the activation, differentiation and effector function (s) of immune cells. In this review, we …
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Y Lu, YT Chan, HY Tan, S Li, N Wang, Y Feng - Molecular cancer, 2020 - Springer
Epigenetics is dynamic and heritable modifications to the genome that occur independently
of DNA sequence. It requires interactions cohesively with various enzymes and other …
of DNA sequence. It requires interactions cohesively with various enzymes and other …
Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
KGK Deepak, R Vempati, GP Nagaraju… - Pharmacological …, 2020 - Elsevier
Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …
Immune checkpoints in the tumor microenvironment
Interactions between immune checkpoints (ICs) and their ligands negatively regulate T cell
activation pathways involved in physiological immune responses against specific antigens …
activation pathways involved in physiological immune responses against specific antigens …
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
Immune checkpoint blockade has shown unprecedented and durable clinical response in a
wide range of cancers. T cell immunoglobulin and mucin domain 3 (TIM3) is an inhibitory …
wide range of cancers. T cell immunoglobulin and mucin domain 3 (TIM3) is an inhibitory …
Combinatorial epigenetics impact of polyphenols and phytochemicals in cancer prevention and therapy
I Arora, M Sharma, TO Tollefsbol - International journal of molecular …, 2019 - mdpi.com
Polyphenols are potent micronutrients that can be found in large quantities in various food
sources and spices. These compounds, also known as phenolics due to their phenolic …
sources and spices. These compounds, also known as phenolics due to their phenolic …
[HTML][HTML] Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
X Chen, X Pan, W Zhang, H Guo, S Cheng, Q He… - … Pharmaceutica Sinica B, 2020 - Elsevier
Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-
L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved …
L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved …
PD-L1 status in breast cancer: current view and perspectives
S Vranic, FS Cyprian, Z Gatalica, J Palazzo - Seminars in cancer biology, 2021 - Elsevier
Breast cancer was traditionally not considered a particularly immunogenic tumor. However,
recent developments have shown that some aggressive triple-negative breast cancers are …
recent developments have shown that some aggressive triple-negative breast cancers are …
[HTML][HTML] Role of epigenetic modifications in inhibitory immune checkpoints in cancer development and progression
A balance between co-inhibitory and co-stimulatory signals in the tumor microenvironment
(TME) is critical to suppress tumor development and progression, primarily via maintaining …
(TME) is critical to suppress tumor development and progression, primarily via maintaining …